EGFR and non-small cell lung carcinoma: Alternatively, osimertinib is an oral and irreversible third generation of EGFR-TKI with potent and selective inhibition of T790M EGFR mutant over WT, which has been widely used for EGFR-T790M-positive NSCLC patients15.